Drug intelligence / Profile preview

diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine

Development stage: Approved
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine (DTPa-HBV-IPV/Hib-MenC-TT) is an investigational heptavalent combination vaccine developed by GSK Biologicals. It is designed as an extension of the licensed hexavalent vaccine Infanrix hexa, incorporating an additional meningococcal serogroup C component conjugated to tetanus toxoid (MenC-TT). The vaccine aims to provide comprehensive protection against seven major pediatric diseases—diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib disease, and meningococcal C disease—within a single immunization series. It has been evaluated in Phase II clinical trials to assess its safety and immunogenicity in infants.

Other names: DTPa-HBV-IPV/Hib-MenC-TT vaccineheptavalent pediatric vaccine

Targets

BCR (Naïve B-cell receptor)PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine.

Explore the full profile